Umair Majid, Christian Holst Bergsland, Anita Sveen, Jarle Bruun, Ina Andrassy Eilertsen, Espen S. Bækkevold, Arild Nesbakken, Sheraz Yaqub, Frode L. Jahnsen, Ragnhild A. Lothe
{"title":"The prognostic effect of tumor-associated macrophages in stage I-III colorectal cancer depends on T cell infiltration","authors":"Umair Majid, Christian Holst Bergsland, Anita Sveen, Jarle Bruun, Ina Andrassy Eilertsen, Espen S. Bækkevold, Arild Nesbakken, Sheraz Yaqub, Frode L. Jahnsen, Ragnhild A. Lothe","doi":"10.1007/s13402-024-00926-w","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Tumor-associated macrophages (TAMs) are associated with unfavorable patient prognosis in many cancer types. However, TAMs are a heterogeneous cell population and subsets have been shown to activate tumor-infiltrating T cells and confer a good patient prognosis. Data on the prognostic value of TAMs in colorectal cancer are conflicting. We investigated the prognostic effect of TAMs in relation to tumor-infiltrating T cells in colorectal cancers.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>The TAM markers CD68 and CD163 were analyzed by multiplex fluorescence immunohistochemistry and digital image analysis on tissue microarrays of 1720 primary colorectal cancers. TAM density in the tumor stroma was scored in relation to T cell density (stromal CD3<sup>+</sup> and epithelial CD8<sup>+</sup> cells) and analyzed in Cox proportional hazards models of 5-year relapse-free survival. Multivariable survival models included clinicopathological factors, MSI status and <i>BRAF</i><sup>V600E</sup> mutation status.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>High TAM density was associated with a favorable 5-year relapse-free survival in a multivariable model of patients with stage I–III tumors (<i>p</i> = 0.004, hazard ratio 0.94, 95% confidence interval 0.90–0.98). However, the prognostic effect was dependent on tumoral T-cell density. High TAM density was associated with a good prognosis in patients who also had high T-cell levels in their tumors, while high TAM density was associated with poorer prognosis in patients with low T-cell levels (<i>p</i><sub>interaction</sub> = 0.0006). This prognostic heterogeneity was found for microsatellite stable tumors separately.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>This study supported a phenotypic heterogeneity of TAMs in colorectal cancer, and showed that combined tumor immunophenotyping of multiple immune cell types improved the prediction of patient prognosis.</p>","PeriodicalId":9690,"journal":{"name":"Cellular Oncology","volume":"2014 1","pages":""},"PeriodicalIF":6.6000,"publicationDate":"2024-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cellular Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13402-024-00926-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Tumor-associated macrophages (TAMs) are associated with unfavorable patient prognosis in many cancer types. However, TAMs are a heterogeneous cell population and subsets have been shown to activate tumor-infiltrating T cells and confer a good patient prognosis. Data on the prognostic value of TAMs in colorectal cancer are conflicting. We investigated the prognostic effect of TAMs in relation to tumor-infiltrating T cells in colorectal cancers.
Methods
The TAM markers CD68 and CD163 were analyzed by multiplex fluorescence immunohistochemistry and digital image analysis on tissue microarrays of 1720 primary colorectal cancers. TAM density in the tumor stroma was scored in relation to T cell density (stromal CD3+ and epithelial CD8+ cells) and analyzed in Cox proportional hazards models of 5-year relapse-free survival. Multivariable survival models included clinicopathological factors, MSI status and BRAFV600E mutation status.
Results
High TAM density was associated with a favorable 5-year relapse-free survival in a multivariable model of patients with stage I–III tumors (p = 0.004, hazard ratio 0.94, 95% confidence interval 0.90–0.98). However, the prognostic effect was dependent on tumoral T-cell density. High TAM density was associated with a good prognosis in patients who also had high T-cell levels in their tumors, while high TAM density was associated with poorer prognosis in patients with low T-cell levels (pinteraction = 0.0006). This prognostic heterogeneity was found for microsatellite stable tumors separately.
Conclusions
This study supported a phenotypic heterogeneity of TAMs in colorectal cancer, and showed that combined tumor immunophenotyping of multiple immune cell types improved the prediction of patient prognosis.
背景在许多癌症类型中,肿瘤相关巨噬细胞(TAMs)与患者的不良预后有关。然而,TAMs 是一个异质性细胞群,其亚群已被证明能激活肿瘤浸润 T 细胞,并使患者预后良好。有关 TAMs 在结直肠癌中的预后价值的数据并不一致。我们研究了 TAM 与肿瘤浸润 T 细胞在结直肠癌中的预后作用。根据 T 细胞密度(基质 CD3+ 细胞和上皮 CD8+ 细胞)对肿瘤基质中的 TAM 密度进行评分,并在 5 年无复发生存率的 Cox 比例危险模型中进行分析。结果在 I-III 期肿瘤患者的多变量模型中,高 TAM 密度与良好的 5 年无复发生存率相关(p = 0.004,危险比 0.94,95% 置信区间 0.90-0.98)。不过,预后效果取决于肿瘤 T 细胞密度。TAM密度高的患者预后良好,而T细胞水平低的患者预后较差(pinteraction = 0.0006)。结论这项研究支持结直肠癌中 TAM 的表型异质性,并表明多种免疫细胞类型的联合肿瘤免疫分型可改善对患者预后的预测。
Cellular OncologyBiochemistry, Genetics and Molecular Biology-Cancer Research
CiteScore
10.40
自引率
1.50%
发文量
0
审稿时长
16 weeks
期刊介绍:
The Official Journal of the International Society for Cellular Oncology
Focuses on translational research
Addresses the conversion of cell biology to clinical applications
Cellular Oncology publishes scientific contributions from various biomedical and clinical disciplines involved in basic and translational cancer research on the cell and tissue level, technical and bioinformatics developments in this area, and clinical applications. This includes a variety of fields like genome technology, micro-arrays and other high-throughput techniques, genomic instability, SNP, DNA methylation, signaling pathways, DNA organization, (sub)microscopic imaging, proteomics, bioinformatics, functional effects of genomics, drug design and development, molecular diagnostics and targeted cancer therapies, genotype-phenotype interactions.
A major goal is to translate the latest developments in these fields from the research laboratory into routine patient management. To this end Cellular Oncology forms a platform of scientific information exchange between molecular biologists and geneticists, technical developers, pathologists, (medical) oncologists and other clinicians involved in the management of cancer patients.
In vitro studies are preferentially supported by validations in tumor tissue with clinicopathological associations.